Emory University School of Nursing, 1520 Clifton Road NE, Atlanta, GA 30322, USA.
Oral Oncol. 2013 Apr;49(4):360-6. doi: 10.1016/j.oraloncology.2012.10.004. Epub 2012 Nov 17.
This study is to identify symptom clusters for head and neck (HNC) patients treated with concurrent chemoradiotherapy.
A secondary data analysis of 684 HNC patients treated on the Radiation Therapy Oncology Group (RTOG) 0129 trial comparing different RT fractionation schedules with concurrent chemotherapy was used to examine clusters. Treatment-related symptoms were measured by clinicians at three time-points during and after chemoradiotherapy using the National Cancer Institute Common Toxicity Criteria v2.0. Exploratory factor analysis was applied to identify symptom clusters, which was further verified by confirmatory factor analysis. Coefficients of congruence and alpha coefficients were employed to examine generalizability of cluster structures over different time-points and in different subgroups.
Two clusters were identified. The HNC specific cluster is composed of radiodermatitis, dysphagia, radiomucositis, dry mouth, pain, taste disturbance, and fatigue. The gastrointestinal (GI) cluster involves nausea, vomiting, and dehydration. With the exception of patients 65years old or older, diagnosed with larynx cancer, or with stage III cancer, the two clusters were generalizable to different subgroups defined by age, gender, race, education, marital status, history of tobacco use, treatments, primary sites, disease stages, and tube feedings, as well as to the three symptom assessment time-points.
The data provides preliminary support for two stable clusters in patients with HNC. These findings may serve to inform the symptom management in clinical practice. Moreover, the findings necessitate future research to examine the generalizability of identified clusters in the late symptom phase or other treatment modalities, and to understand the underlying biological mechanism.
本研究旨在确定接受同期放化疗的头颈部(HNC)患者的症状群。
对接受放疗肿瘤组(RTOG)0129 试验的 684 例 HNC 患者的二次数据分析,该试验比较了不同的放疗分割方案与同期化疗的疗效,以检查聚类。使用国家癌症研究所通用毒性标准 v2.0 由临床医生在放化疗期间和之后的三个时间点测量与治疗相关的症状。采用探索性因子分析识别症状群,并用验证性因子分析进一步验证。一致性系数和 alpha 系数用于检验不同时间点和不同亚组中聚类结构的可推广性。
确定了两个聚类。HNC 特异性聚类由放射性皮炎、吞咽困难、放射性黏膜炎、口干、疼痛、味觉障碍和疲劳组成。胃肠道(GI)聚类涉及恶心、呕吐和脱水。除了年龄在 65 岁或以上、诊断为喉癌或处于 III 期癌症的患者,以及两个聚类在年龄、性别、种族、教育程度、婚姻状况、吸烟史、治疗、原发部位、疾病分期和管饲等不同亚组以及三个症状评估时间点都具有可推广性。
数据初步支持 HNC 患者存在两个稳定的聚类。这些发现可能有助于为临床实践中的症状管理提供信息。此外,这些发现需要进一步研究以检验在晚期症状阶段或其他治疗方式中确定的聚类的可推广性,并了解潜在的生物学机制。